Tabalumab Auto-Injector + Tabalumab Prefilled Syringe
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Lupus Erythematosus, Systemic
Conditions
Lupus Erythematosus, Systemic
Trial Timeline
Jan 1, 2014 → Nov 1, 2015
NCT ID
NCT02041091About Tabalumab Auto-Injector + Tabalumab Prefilled Syringe
Tabalumab Auto-Injector + Tabalumab Prefilled Syringe is a phase 3 stage product being developed by Eli Lilly for Lupus Erythematosus, Systemic. The current trial status is terminated. This product is registered under clinical trial identifier NCT02041091. Target conditions include Lupus Erythematosus, Systemic.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02041091 | Phase 3 | Terminated |
| NCT01676701 | Phase 3 | Terminated |
Competing Products
20 competing products in Lupus Erythematosus, Systemic
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Baricitinib + Placebo | Eli Lilly | Phase 2 | 52 |
| DS-7011a + Placebo | Daiichi Sankyo | Phase 1 | 33 |
| DS-7011a + Placebo | Daiichi Sankyo | Phase 1/2 | 41 |
| tacrolimus | Astellas Pharma | Phase 3 | 77 |
| Tacrolimus | Astellas Pharma | Pre-clinical | 23 |
| tacrolimus capsule + tacrolimus placebo + leflunomide tablet + leflunomide placebo + prednisone | Astellas Pharma | Phase 3 | 77 |
| tacrolimus | Astellas Pharma | Approved | 85 |
| Tacrolimus capsules + Cyclophosphamide injections + Prednisone | Astellas Pharma | Phase 3 | 77 |
| E6742 | Eisai | Phase 1/2 | 41 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 77 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 77 |
| LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of Care | Eli Lilly | Phase 3 | 77 |
| LY3361237 + Placebo | Eli Lilly | Phase 2 | 52 |
| LY2127399 + Placebo | Eli Lilly | Phase 3 | 77 |
| LY3361237 + Placebo | Eli Lilly | Phase 1 | 33 |
| LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks | Eli Lilly | Phase 3 | 77 |
| Baricitinib + Placebo | Eli Lilly | Phase 3 | 77 |
| LY3471851 + Placebo | Eli Lilly | Phase 1 | 33 |
| LY3471851 + Placebo | Eli Lilly | Phase 2 | 52 |
| Itolizumab [Bmab 600] | Biocon | Phase 1 | 33 |